Operating results for the first 9 months of 2024: PROMOMED showed revenue growth of 34%, which is twice the growth of the pharmaceutical market (17%)

Operating results for the first 9 months of 2024: PROMOMED showed revenue growth of 34%[1], which is twice the growth of the pharmaceutical market (17%[2]). The company confirms the forecast of key financial indicators, increases the speed of new product development, demonstrates steady growth and intensive development.

December 02, 2024, Moscow – PJSC PROMOMED (MOEX: PRMD) (formerly –PROMOMED", the "Company", and together with its subsidiaries, the "Group") announces the Group's operating results for the 9 months of 2024 ended September 30, 2024.

OPERATIONAL INDICATORS

• The company has completed a cycle of research, development and registration and is launching the innovative drug Velgia^®, designed to treat overweight and obesity of any severity and prevent the risks of developing cardiovascular disasters. Velgia^® opens up almost limitless possibilities of effective therapy that were not previously available to patients in the Russian Federation. The drug is of revolutionary importance, as it is intended for the widest groups of the adult population, regardless of gender, age and concomitant diseases[3]. The drug is already available for the healthcare system.
• The endocrinological (treatment of overweight, obesity and diabetes mellitus) and Oncological portfolios are key for the Company.
• In 9 months of 2024, the Endocrinology portfolio showed steady growth. The portfolio evolution index[4] was 143.6 (43.6% ahead of the relevant market growth).
• The Company's oncology portfolio has also demonstrated steady growth. The evolution index for 9 months of 2024 was 141.6 (ahead of the growth of the relevant market by 41.6%).
• Thus, the Company is confidently outpacing the growth of the fastest-growing and high-margin markets.
• In 9 months of 2024, the Company expanded its scientific activities and conducted 51 medical studies. A significant increase in the number of studies conducted is due to the implementation of the announced strategy to bring innovative and import-substituting drugs to the market.
• In 9 months of 2024, the Company received registration certificates for 34 medicines.
• In 9 months of 2024, the Company has registered 14 new patents.
• At the end of Q3 2024, the number of proprietary trademarks increased to 503, which is 133 more than at the end of Q3 2023. The growing number of intellectual property objects is associated with the consistent implementation of innovation activities and the protection of the latest developments, and confirms the Company's attention to increasing the value of intangible assets.
• Another revolutionary step was the preparation of a portfolio of innovative and import-substituting drugs for animal health. So, the production areaIn the 3rd quarter of 2024, the spacecraft of JSC Biochemik successfully passed the inspection of the regulator and received a license for the production of veterinary drugs. The company is preparing a number of breakthrough veterinary solutions, the launch of which will begin as early as 2025.

FINANCIAL INDICATORS

• In 9 months of 2024, the Company's revenue increased by 34% to 10,657 million rubles. The Company's revenue growth rate is twice as high as the growth rate of the pharmaceutical market, which was about 17%.
• The share of drugs from the Endocrinological and Oncological portfolios in revenue for 9 months of 2024 was 53%. The fundamental change in revenue structure, as predicted by PROMOMED, is due to the faster growth rates of these segments, as well as the introduction of new drugs from the field of Endocrinology and Oncology to the market.
• In the Endocrinology segment, revenue for 9 months of 2024 increased by 49% compared to 9 months of 2023 and amounted to 3.1 billion rubles, due to successful sales of new products for the treatment of overweight and obesity - Enligria®, and for the treatment of diabetes - Quincenta®. The company expects accelerated revenue growth in this therapeutic area, especially after the launch of sales of the innovative Velgia® drug in Q4 2024, intended for the widest range of overweight and obese patients of any severity.
• In the Oncology segment, revenue for 9 months of 2024 increased by 58% compared to 9 months of 2023 and amounted to 2.5 billion rubles. The main growth driver was the launch of drugs in oncohematology and oncourology on the market.
• As of September 30, 2024, Net debt/LTM EBITDA decreased compared to June 30, 2024 and amounted to 2.3x.
• The company confirms its financial forecast for 2024.

staff

• The total number of employees as of September 30, 2024 increased by 12% to 2,181 people.
• The main drivers of headcount growth are the R&D, Sales, Marketing, and IT Digital Transformation divisions.
• The number of employees in R&D increased by 19% to 446 people as of September 30, 2024.

Ilya Bardin-Denisov, General Director of PROMOMED DM LLC, commented:

"The company is successfully implementing a strategy to bring innovative products to the market, was the first to launch a full line of drugs for the treatment of obesity, and is increasing the share of biotechnological drugs. Thanks to well-planned tactics, a successful withdrawal of products in Oncology was carried out. In the retail segment, increased promotion and investments in TV advertising have allowed us to achieve double-digit growth rates in relevant markets."

About the Company

PJSC PROMOMED is a leading innovative biopharmaceutical company with the potential for significant growth in promising segments of the pharmaceutical market.

The Company's structure includes its own unique world-class R&D center and a high-tech enterprise, the Biochemist plant. Thanks to this, PROMOMED implements the concept of a full production cycle "from Idea to Molecule, from Molecule to Patient", promptly responds to the current needs of the industry, and also implements the latest technologies to create innovative medicines. The company develops a diversified portfolio of more than 330 medicines in the TOP 10 segments of the pharmaceutical market. The Company's portfolio includes "blockbuster" drugs and innovative biotechnological drugs that have no analogues on the Russian market. Based on its own developments, the Company produces drugs for the treatment of socially significant diseases: oncology, diabetes, obesity, neurology, infectious diseases, rheumatology, etc. Thanks to its own innovative chemical technologies and biotechnologies, as well as modern production facilities, the Company is an active participant in the system of ensuring national drug safety and import independence of the country.

Contacts

border="1" cellspacing="0" cellpadding="0" style="border-collapse: collapse;">

For investors

For the media

ir@promomed.pro   

pr@promomed.pro

Statement of limitation of liability

This message and the information contained therein are not:

• an offer to purchase any securities,
• an invitation to make offers for the purchase of any securities,
• as part of such offers or invitations,
• securities advertising in the Russian Federation or other jurisdictions,
• by encouraging or recommending transactions,
• it is also not subject to interpretation as such.

Neither this communication nor any part of it is the basis for concluding any transaction or incurring any obligation, they cannot be used in connection with any transactions or obligations or serve as an incentive to conclude any transactions or assume any obligations.

Neither this announcement nor any part of it should serve as a basis for making any investment decisions.

The publication of this communication does not imply investment consulting (in the meaning defined in the legislation of the Russian Federation (including Federal Law No. 39-FZ of April 22, 1996 "On the Securities Market"). The information provided in this message is not an individual investment recommendation, and the financial instruments or transactions mentioned in it may not meet your investment profile and investment goals (expectations). It is your task to determine whether a financial instrument or operation matches your interests, investment goals, investment horizon, and acceptable risk level. PJSC PROMOMED (hereinafter referred to as the Company) is not responsible for possible losses in the event of transactions or investments in financial instruments mentioned in this information, and does not recommend using this information as the sole source of information when making an investment decision.

Before making an investment decision on making or not making transactions with the Company's shares, it is necessary, among other things, to familiarize yourself with the information disclosed on the Company's web page. https://e-disclosure.ru/portal/company.aspx?id=38533 .

The information contained in this announcement may include estimates and other forward-looking statements regarding the intentions, plans, future events, financial, operational or other activities of the Group. Actual events, calculations and results of their activities may differ materially from those contained or anticipated in the forward-looking statements, words and expressions contained in this communication or related materials due to the influence of various external and internal factors (general economic conditions; risks associated with the specifics of the Company's activities, including those that cannot be controlled by the Company; changes in market conditions in the industry in which the Company and the Group operate; geopolitical and other factors and risks). The indication of goals, potential, growth opportunities or other indicators is not a guarantee of the realization of these goals, potential, opportunities.

The methodology for determining and calculating the operational and financial indicators of a Company may differ from the methodology used by other individuals, companies or organizations.

The Company or persons belonging to the Group, their directors, participants (shareholders), employees, representatives do not provide any guarantees or assurances confirming the accuracy, completeness or unambiguous nature of the information and information contained in this communication or related materials, and do not assume any obligations or obligations to updating them.

---

%B5%D1%81.%202024%20%D0%9F%D0%A0%D0%9E%D0%9C%D0%9E%D0%9C%D0%95%D0%94.docx#_ftnref1">[1] Hereafter: financial indicators based on data management reporting.

[2] Source: IQVIA.

[3] There are contraindications, and a specialist's consultation is necessary before use.

[4] Evolution Index (EI) is an evolution index calculated to assess the progress of a product and/or a company's product portfolio in the market, reflecting the growth rate of a product compared to the growth of its relevant market. Values above 100 indicate by how many percentage points the product or portfolio is growing faster than the market.